1. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Issue 4 (24th January 2017) Authors: Reyes-Soffer, Gissette; Pavlyha, Marianna; Ngai, Colleen; Thomas, Tiffany; Holleran, Stephen; Ramakrishnan, Rajasekhar; Karmally, Wahida; Nandakumar, Renu; Fontanez, Nelson; Obunike, Joseph; Marcovina, Santica M.; Lichtenstein, Alice H.; Matthan, Nirupa R.; Matta, James; Maroccia, Magali; Becue, ... Journal: Circulation Issue: Volume 135:Issue 4(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. Issue 9 (September 2018) Authors: Basu, Debapriya; Huggins, Lesley-Ann; Scerbo, Diego; Obunike, Joseph; Mullick, Adam E.; Rothenberg, Paul L.; Di Prospero, Nicholas A.; Eckel, Robert H.; Goldberg, Ira J. Journal: Arteriosclerosis, thrombosis, and vascular biology Issue: Volume 38:Issue 9(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗